Palifermin for management of treatment-induced oral mucositis in cancer patients

Biologics: Targets and Therapy

Volumn 3, Issue , 2009, Pages 111-116

  Barasch, Andrei ^a   Epstein, Joel ^b   Tilashalski, Ken ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Cancer; Mucositis; Palifermin; Therapy

Indexed keywords

EID: 65349176511     PISSN: 11775475     EISSN: 11775491     Source Type: Journal    
DOI: 10.2147/BTT.S3914     Document Type: Review

References (41)

1. Raber-Durlacher JE, Barasch A, Peterson DE, et al. Oral complications and management considerations in patients treated with high-dose cancer chemotherapy. Support Cancer Ther. 2004;4:219-230.
2. Sonis ST. The pathobiology of mucositis. Nat Rev Cancer. 2004;4:277-284.
3. Barasch A, Peterson DE. Risk factors for ulcerative oral mucositis in cancer patients: unanswered questions. Oral Oncol. 2003;39:91-100.
4. Sonis ST, Oster G, Fuchs H, et al. Oral mucositis and the clinical and economic outcomes of hematopoietic stem-cell transplantation. J Cli Oncol. 2001;19:2201-2205.
5. Rubin JS, Bottaro DP, Chedid M, et al. Keratinocyte growth factor. Cell Biol Int. 1995;19:399-411.
6. MacDonald KP, Hill GR. Keratinocyte growth factor (KGF) in hematology and oncology. Curr Pharm Des. 2002;8:395-403.
7. McKeown ST, Hyland PL, Locke M, Mackenzie IC, Irwin CR. Keratinocyte growth factor and scatter factor expression by regionally defined oral fibroblasts. Eur J Oral Sci. 2003;111:42-50.
8. Jeschke MG, Richter G, Hofstadter F, Herndon DN, Perez-Polo JR, Jauch KW. Non-viral liposomal Keratinocyte growth factor (KGF) cDNA gene transfer improves dermal and epidermal regeneration through stimulation of epithelial and mesenchymal factors. Gene Ther. 2002;9:1065-1074.
9. Farrell CL, Bready JV, Rex KL, et al. Keratinocyte growth factor protects mice from chemotherapy and radiation-induced gastrointestinal injury and mortality. Cancer Res. 1998;58:933-939.
10. Farrell CL, Rex KL Chen JN, et al. The effects of keratinocyte growth factor inpreclinical models of mucositis. Cell Prolif. 2002; 35 Suppl 1:78-85.
11. Ning S, Shui C, Khan WB, et al. effects of keratinocyte growth factor on the proliferation and radiation survival of human squamous cell carcinoma cell lines in vitro and in vivo. Int J Rad Oncol Biol Phys. 1998;40:177-187.
12. Farrell CL, Rex KL, Kaufman SA, et al. Effects of keratinocyte growth factor in the squamous epithelium of the upper aerodigestive tract of normal and irradiated mice. Int J Radiat Biol. 1999;75:609-620.
13. Potten CS, Booth D, Cragg NJ, et al. Cell kinetic studies in the murine ventral tongue epithelium: mucositis induced by radiation and its protection by pretreatment with keratinocyte growth factor (KGF). Cell Prolif. 2002;35 (suppl 1):32-47.
14. Dorr W, Noack R, Spekl K, Farrell CL. Modification of oral mucositis by keratinocyte growth factor: single radiation exposure. Int J Radiat Biol. 2001;77:341-347.
15. Dorr W, Spekl K, Farrell CL. The effect of keratinocyte growth factor on healing of manifest radiation ulcers in mouse tongue epithelium. Cell Prolif. 2002;35 (suppl 1):86-92.
16. Panoskaltsis-Mortari A, Taylor PA, Rubin JS, et al. Keratinocyte growth factor facilitates alloengraftment and ameliorates graft-versus-host disease in mice by a mechanism independent of repair of conditioning-induced tissue injury. Blood. 2000;96:4350-4356.
17. Seggwiss R, Lore K, Guenaga FJ, et al. Keratinocyte growth factor auguments immune reconstitution after autologous hematopoietic progenitor cell transplantation in rhesus monkeys. Blood. 2007;110:441-449.
18. Lombaert IM, Brunsting JF, Wierenga PK, Kampinga HH, de Haan G, Coppes RP. Keratinocyte growth factor prevents radiationdamage to salivary glands by expansion of the stem/progenitor pool. Stem Cells. 2008;26:2595-2601.
19. Nguyen TN, Zang XP, Pento JT. Keratinocyte growth factor stimulates the migration and proliferation of breast cancer cells in a culture wounding model. Pharmacol Res. 2002;46:179-183.
20. Zang XP, Nguyen TN, Pento JT. Specific and non-specific KGF-induced breast cancer cell motility. Anticancer Res. 2002;22:2539-2545.
21. Taniguchi F, Harada T, Sakamoto Y, et al. Activation of mitogen-activated protein kinase pathway by keratinocyte growth factor or fibroblast growth factor-10 promotes cell proliferation in human endometrial carcinoma cells. J Clin Endocrinol Metab. 2003;88:773-780.
22. Rotolo S, Ceccarelli S, Romano F, Frati L, Marchese C, Angeloni A. Silencing of keratinocyte growth factor receptor restores 5-fluorouracil and tamoxifen efficacy in responsive cancer cells. PLoS ONE. 2008; 3:e2528.
23. Brake R, Starnes C, Lu J, et al. effects of palifermin on antitumor activity of chemotherapeutic and biological agents in human head and neck and colorectal carcinoma xenograft models. Mol Cancer Res. 2008;6:1337-1346.
24. Gibson RJ, Keefe DM, Clarke JM, et al. The effect of keratinocyte growth factor on tumor growth and small intestinal mucositis after chemotherapy in the rat with breast cancer. Cancer Chemother Pharmacol. 2002;50:53-58.
25. Brizel DM, Herman T, Goffinet D, et al. A phase I/II trial of escalating doses of recombinant human keratinocyte growth factor (rHuKGF) in head and neck cancer (HNC) patients receiving radiotherapy (RT) with concurrent chemotherapy (CCT). (Abstr). Int J Radiat Oncol Biol Phys. 2001;51 suppl 1:40.
26. Brizel DM, Murphy BA, Rosenthal DI, et al. Phase II study of palifermin and concurrent chemoradiation in head and neck squamous cell carcinoma. J Clin Oncol. 2008;26:2489-2496.
27. Meropol NJ, somer RA, Gutheil J, et al. Randomized phase I trial of recombinant human keratinocyte growth factor plus chemotherapy: potential role as mucosal protectant. J Clin Oncol. 2003;21:1452-1458.
28. Spielberger RT, Stiff P, Emmanouilides C, et al. Efficacy of recombinant human keratinocyte growth factor (rHuKGF) in reducing mucositis in patients with hematologic malignancies undergoing autologous peripheral blood progenitor cell transplantation (auto-PBPCT) after radiation-based conditioning: results of a phase 2 trial [Abstract]. Proc Am Soc Clin Oncol. 2001;20:7a.
29. Spielberger R, Stiff P, Bensinger W, et al. Palifermin for oral mucositis after intensive therapy for hematologic cancers. N Engl J Med. 2004;351:2590-2598.
30. Horsley P, Bauer JD, Mazkowiack R, Gardner R, Bashford J. Palifermin improves severe mucositis, swallowing problems, nutrition impact symptoms, and length of stay in patients undergoing hematopoietic stem cell transplantation. Support Care Cancer. 2007;15:105-109.
31. Rosen LS, Abdi E, Davis ID, et al. Palifermin reduces the incidence of oral mucositis in patients with metastatic colorectal cancer treated with fluorouracil-based chemotherapy. J Clin Oncol. 2006;24:5194-5200.
32. Schmidt E, Thoennissen NH, Rudat A, et al. Use of palifermin for the prevention of high-dose methotrexate-induced oral mucositis. Ann Oncol. 2008;19:1644-1649.
33. Elting LS, Shih YC, Stiff PJ, et al. Economic impact of palifermin on the cost of hospitalization for autologous hematopoietic stem-cell transplant: analysis of phase 3 trial results. Biol Blood Marrow Transplant. 2007;13:806-813.
34. Langner S, Staber P, Schub N, et al. Palifermin reduces incidence and severity of oral mucositis in allogeneic stem-cell transplant recipients. Bone Marrow Transplant. 2008;42:275-279.
35. Levine JE, Blazar BR, DeFor T, Ferrara JL, Weisdorf DJ. Long-term follow-up of a phase I/II randomized, placebo-controlled trial of palifermin to prevent graft-versus-host disease (GVHD) after related donor allogeneic hematopoietic cell transplantation (HCT). Biol Blood Marrow Transplant. 2008;14:1017-1021.
36. Nasilowska-Adamska B, Rzepecki P, Manko J, et al. The influence of palifermin (Kepivance) on oral mucoasitis and acute graft versus host disease in patients with hematological diseases undergoing hematopoietic stem cell transplant. Bone Marrow Transplant. 2007;40:983-938.
37. Alderson R, Gohari-Fritsch S, Olsen H, Roschke V, Vance C, Connolly P. In vitro and in vivo effects of repifermin (keratinocyte growth factor-2, KGF-2) on human carcinoma cells. Cancer Chemother Pharmacol. 2002;50:202-212.
38. Freytes CO, Ratanatharathorn V, Taylor C, et al. Phase I/II randomized trial evaluating the safety and clinical effects of repifermin administered to reduce mucositis in patients undergoing autologous hematopoietic stem cell transplantation. Clin Cancer Res. 2004;10:8318-8324.
39. Alvarez E Fey EG, Valax P, et al. Preclinical characterization of CG53135 (FGF-20) in radiation and concomitant chemotherapy/radiation-induced oral mucositis. Clin Cancer Res. 2003;9:3454-3461.
40. Alvarez E, Gerlach VL, Gerwien RW, et al. single-dose prevention or short-term treatment with fibroblast growth factor-20 (CG53135-05) reduces the severity and duration of oral mucositis. Support Cancer Ther. 2005;2:122-127.
41. Shuster MW, Shore TB, Harpel JG, et al. Safety and tolerability of velafermin (CG53135-05) in patients receiving high-dose chemotherapy and autologous peripheral blood stem cell transplant. Support Care Cancer. 2008;16:477-483.